Larimar Therapeutics, Inc.
LRMRHealthcareNASDAQBiotechnology · Last scanned Jun 2, 2026
Scan Results
Daily timeframeLarimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. The company carries a $364.6M market cap, placing it firmly in the small-cap category. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Market Cap
$364.6M
Beta
0.91
P/E (TTM)
—
P/E (Fwd)
-2.86
EPS (TTM)
$-2.12
EPS (Fwd)
$-1.23
ROE
-109.8%
ROA
-56.9%
Cash
$200.4M
Total Debt
$3.8M
Free CF
-$71.3M
52W Change
45.6%
Annual Financials
Cash vs Debt
With $200.4M in cash and $3.8M in debt, LRMR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$71.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -109.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LRMR.